TGI chemotherapy
Phase 2Small molecule
TGI chemotherapy is one of 49 small molecule programs targeting Rhabdomyosarcoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
68 competitors in Rhabdomyosarcoma
#DrugCompanyPhaseTrials
1Cytoxan
BBaxter Healthcare Corporation
Phase 3
Oncovin
Eli LillyPhase 3
Cosmegen
RRECORDATI GROUP
Phase 3
Oncovin
EEastern Cooperative Oncology Group
Phase 3
Camptosar
EEastern Cooperative Oncology Group
Phase 3
Ifex
BBaxter Healthcare Corporation
Phase 3
Navelbine
PPierre Fabre Medicament
Phase 3
Navelbine
GGynecologic Oncology Group
Phase 3
Paraplatin
AAvyxa
Phase 3
Hycamtin
GGynecologic Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Rhabdomyosarcoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TGI chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details